期刊文献+

新型抗凝血肝素铁纳米粒的制备及性质研究 被引量:2

Preparation and Characterization of Novel Anticoagulant Iron Heparin Nanopariticles
下载PDF
导出
摘要 目的制备一种新型具有抗凝血活性的肝素铁纳米粒。方法通过Fe3+与肝素复合的方法制备出肝素铁纳米粒;通过激光粒度仪(DLS)、Zeta电位仪、扫描力显微镜(SFM)、傅立叶红外光谱(FT-IR)分析了肝素铁纳米粒的粒径分布、表面电位、粒子形态及偶联关系;通过甲苯胺蓝染色法测定了制备过程中剩余肝素浓度来计算肝素铁纳米粒中肝素含量;通过活化部分凝血激酶时间(APTT)的方法测定肝素铁纳米粒的抗凝血活性。结果Fe3+与肝素按不同比例复合可制备出粒径在(139.0~219.9)nm、Zeta电位在(-22.5^-36.5)mV的纳米粒;红外光谱显示,肝素的硫酸基团与铁离子发生了离子复合作用;Fe3+与肝素按不同比例复合制备出的纳米粒中肝素含量在29.5%~33.1%,抗凝血活性在43.2~46.5u.mg-1。结论Fe3+与肝素复合的方法可制备出一种新型具有抗凝血活性的肝素铁纳米粒。 OBJECTIVE The aim of current study was to prepare and characterize novel iron heparin nanoparticles. METHODS Iron heparin nanopaticles were obtained through ionic complexation between Fe^3+ and heparin. Iron heparin nanoparticles were characterized using dynamic light scattering (DLS), Zeta potential, scanning force microscopy (SFM) and fourier infrared spectroscopy (FT-IR). The content of heparin of iron heparin nanoparticles were determined by toluidine blue heparin assay. The anticoagulant activity of iron heparin nanoparticles were tested by activated partial thromboplastin time (APTF) assay. RESULTS Size (139.0-219. 9) nm and Zeta potential ( -22. 5 - -36. 5 ) mV of iron heparin nanoparticles were conveniently modulated by varying ratio of Fe^3+ and heparin. IR result showed Fe^3+ interacted with O-sulphate groups. The content of heparin of iron heparin nanoparicles were in range of 29. 5% -33.1% and anticoagulant activity of iron heparin nanoparicles were in range of 43.2 - 46. 5 u·mg^-1 by varying ratio of Fe^3+ and heparin. CONCLUSION Novel anticoagulant iron heparin nanoparticles were fabricated by using only complexation of Fe^3+ and heparin.
出处 《中国药学杂志》 CAS CSCD 北大核心 2008年第20期1535-1538,共4页 Chinese Pharmaceutical Journal
基金 教育部高等学校科技创新工程重大项目培育资助项目(707021) 新世纪优秀人才支持计划(NCET-05-0335)
关键词 肝素 抗凝血 药物 纳米粒 heparin anticoagulants drugs nanoparticles
  • 相关文献

参考文献10

  • 1HIRSH J, WARKENTIN T E, RASCHKE R, et al. Heparin and low-molecular-weight-heparin [ J]. Chest, 1998,114(5 ) :489-510.
  • 2顾健,杨军,张春燕,张海英,李玉珍.6种市售低分子肝素的分子特性及生物活性的比较[J].中国药学杂志,2007,42(6):461-465. 被引量:8
  • 3HIRSH J, ANAND S S, HALPERIN J L, et al. Guide to anticoagulant therapy:heparin a statement for healthcare professionals from the American heart association[J]. Circulation, 2001, 103 (24) :2994-3018.
  • 4MCAVOY T J. The biologic half-life of heparin [ J ]. Clin Pharmacol Ther, 1979,25(3) :372-379.
  • 5PETITOU M, HERAULT J P, BERNAT A, et al. Synthesis of thrombin-irthibiting heparin mimeties without side effects [ J ]. Nature, 1999,398(6726) :417-422.
  • 6MENG L, XIULI Y, ZHIFEI D, et al. Stabilized hemocompatible coating of nitinol devices based on Photo-Cross-Linked Alginate/ Heparin Multilayer [ J ]. Lanbmuir ,2007 ,23 ( 18 ) :9378-9385.
  • 7GRANT D, LONG W F, WILLIAMSON F B. Infrared spectro scopy of heparin-cation complexes [ J ]. Biochem J, 1987, 244 ( 1 ) : 143-149.
  • 8MOGHIMI S M, HUNTER A C, MURRAY J C. Long-cimulating and target-specific nanoparticles :theory to practice[ J]. Pharmacol Rev, 2001,53(2):283-318.
  • 9SIPOS P, BERKESI O, TOMBACZ E, et al. Formation of spherical iron ( Ⅲ ) oxyhydroxide nanoparticles sterically stabilized by chitosan in aqueous solutions [ J ]. J Inorg Biochem, 2003, 95 ( 1 ) : 55-63.
  • 10LEVER R, PAGE C P. Novel drug development opportunities for heparin[J]. Nat Rev Drug Discov, 2002, 1(2) :140-148.

二级参考文献4

共引文献7

同被引文献46

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部